Long-term safety of risankizumab in PsA and PsO pts Over 5k pts, over 4 years Rates of AEs remained low malignancy inci
Tweet Content
Long-term safety of risankizumab in PsA and PsO pts
Over 5k pts, over 4 years
Rates of AEs remained low
malignancy incidence remains low
@RheumNow #ACR23 Abs#1422 https://t.co/GBFke3XmQD
Show on Archive Page
On
Display in Search Results
On
PDQ
Off